000128195 001__ 128195
000128195 005__ 20240228135047.0
000128195 0247_ $$2doi$$a10.1007/s00401-014-1326-7
000128195 0247_ $$2pmid$$apmid:25143301
000128195 0247_ $$2ISSN$$a0001-6322
000128195 0247_ $$2ISSN$$a1432-0533
000128195 0247_ $$2altmetric$$aaltmetric:2768293
000128195 037__ $$aDKFZ-2017-04212
000128195 041__ $$aeng
000128195 082__ $$a610
000128195 1001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b0$$eFirst author$$udkfz
000128195 245__ $$aFarewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
000128195 260__ $$aBerlin$$bSpringer$$c2014
000128195 3367_ $$2DRIVER$$aarticle
000128195 3367_ $$2DataCite$$aOutput Types/Journal article
000128195 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523450337_27430
000128195 3367_ $$2BibTeX$$aARTICLE
000128195 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128195 3367_ $$00$$2EndNote$$aJournal Article
000128195 520__ $$aAstrocytoma and oligodendroglioma are histologically and genetically well-defined entities. The majority of astrocytomas harbor concurrent TP53 and ATRX mutations, while most oligodendrogliomas carry the 1p/19q co-deletion. Both entities share high frequencies of IDH mutations. In contrast, oligoastrocytomas (OA) appear less clearly defined and, therefore, there is an ongoing debate whether these tumors indeed constitute an entity or whether they represent a mixed bag containing both astrocytomas and oligodendrogliomas. We investigated 43 OA diagnosed in different institutions employing histology, immunohistochemistry and in situ hybridization addressing surrogates for the molecular genetic markers IDH1R132H, TP53, ATRX and 1p/19q loss. In all but one OA the combination of nuclear p53 accumulation and ATRX loss was mutually exclusive with 1p/19q co-deletion. In 31/43 OA, only alterations typical for oligodendroglioma were observed, while in 11/43 OA, only indicators for mutations typical for astrocytomas were detected. A single case exhibited a distinct pattern, nuclear expression of p53, ATRX loss, IDH1 mutation and partial 1p/19q loss. However, this was the only patient undergoing radiotherapy prior to surgery, possibly contributing to the acquisition of this uncommon combination. In OA with oligodendroglioma typical alterations, the portions corresponding to astrocytic part were determined as reactive, while in OA with astrocytoma typical alterations the portions corresponding to oligodendroglial differentiation were neoplastic. These data provide strong evidence against the existence of an independent OA entity.
000128195 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000128195 588__ $$aDataset connected to CrossRef, PubMed,
000128195 650_7 $$2NLM Chemicals$$aNuclear Proteins
000128195 650_7 $$2NLM Chemicals$$aTumor Suppressor Protein p53
000128195 650_7 $$0EC 1.1.1.41$$2NLM Chemicals$$aIsocitrate Dehydrogenase
000128195 650_7 $$0EC 1.1.1.42.$$2NLM Chemicals$$aIDH1 protein, human
000128195 650_7 $$0EC 3.6.4.-$$2NLM Chemicals$$aDNA Helicases
000128195 650_7 $$0EC 3.6.4.12$$2NLM Chemicals$$aATRX protein, human
000128195 7001_ $$0P:(DE-HGF)0$$aReuss, David$$b1
000128195 7001_ $$0P:(DE-HGF)0$$aKoelsche, Christian$$b2
000128195 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b3$$udkfz
000128195 7001_ $$0P:(DE-HGF)0$$aSchittenhelm, Jens$$b4
000128195 7001_ $$aHeim, Stephanie$$b5
000128195 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b6$$udkfz
000128195 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b7$$udkfz
000128195 7001_ $$0P:(DE-He78)c146c0b611b8fb654444ec078766f5ea$$aHerold-Mende, Christel$$b8$$udkfz
000128195 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b9$$udkfz
000128195 7001_ $$aMueller, Wolf$$b10
000128195 7001_ $$aHartmann, Christian$$b11
000128195 7001_ $$aPaulus, Werner$$b12
000128195 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b13$$eLast author$$udkfz
000128195 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-014-1326-7$$gVol. 128, no. 4, p. 551 - 559$$n4$$p551 - 559$$tActa neuropathologica$$v128$$x1432-0533$$y2014
000128195 909CO $$ooai:inrepo02.dkfz.de:128195$$pVDB
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c146c0b611b8fb654444ec078766f5ea$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128195 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000128195 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000128195 9141_ $$y2014
000128195 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000128195 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000128195 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128195 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128195 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128195 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128195 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128195 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128195 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128195 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128195 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128195 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128195 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128195 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000128195 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000128195 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x1
000128195 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x2
000128195 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000128195 9201_ $$0I:(DE-He78)L801-20160331$$kL801$$lDKTK Tübingen$$x4
000128195 980__ $$ajournal
000128195 980__ $$aVDB
000128195 980__ $$aI:(DE-He78)G380-20160331
000128195 980__ $$aI:(DE-He78)B062-20160331
000128195 980__ $$aI:(DE-He78)G370-20160331
000128195 980__ $$aI:(DE-He78)L101-20160331
000128195 980__ $$aI:(DE-He78)L801-20160331
000128195 980__ $$aUNRESTRICTED